6 Results for "

antinecroptotic activity

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "antinecroptotic activity" in MCE Product Catalog:

Cat. No.: HY-169074
CAS No.: 2924858-30-8
Research Areas:  

Cancer

Thalidomide-N-methylpiperazine is an E3 Ligase Ligand-Linker Conjugate. Thalidomide-N-methylpiperazine can be used to synthesize PROTAC MLKL Degrader-2 (HY-169072) to exhibit antinecroptotic activity on human cell lines and effectively degrade MLKL in the HT-29 xenograft mouse model .
loading...
    loading...
Cat. No.: HY-157963
CAS No.: 3031534-16-1
Target:  

RIP kinase Necroptosis

Research Areas:  

Inflammation/Immunology Cancer

RIPK1-IN-23 (compound 19) is a RIPK1 inhibitor with potent anti-necroptotic effects in HT-29 cells (EC50 of 1.7 nM). RIPK1-IN-23 shows anti-inflammatory activities .
loading...
    loading...
Cat. No.: HY-149052
CAS No.: 2919801-86-6
SZM-1209 is an orally active, potent and specific RIPK1 inhibitor, with a Kd of 85 nM. SZM-1209 exhibits high anti-necroptotic activity (EC50=22.4 ± 8.1 nM). SZM-1209 shows anti-SIRS (systemic inflammatory response syndrome), and anti-ALI (acute lung injury) effects .
loading...
    loading...
Cat. No.: HY-170232
Target:  

RIP kinase

Research Areas:  

Inflammation/Immunology

RIPK1-IN-29 (Compound 22) is a RIPK1 inhibitor, with an IC50 of 6.9 nM. RIPK1-IN-29 exerts anti-necroptotic (Apoptosis) activity by inhibiting RIPK1. In a TNF-α-induced in vivo inflammation model, at a dose of 10 mg/kg, RIPK1-IN-29 can protect mice from hypothermia and death. RIPK1-IN-29 can be applied to the research field of inflammatory diseases .
loading...
    loading...
Cat. No.: HY-179680
CAS No.: 3092834-30-2
RIPK1-IN-38 is an orally active RIPK1 inhibitor with an IC50 value of 27 nM. RIPK1-IN-38 can inhibit the phosphorylation of RIPK1 and its downstream signaling molecules RIPK3 and MLKL. RIPK1-IN-38 exhibits anti-necroptotic activity. RIPK1-IN-38 has excellent anti-inflammatory efficacy in both the SIRS model and GVHD model. RIPK1-IN-38 can be used for the research of inflammatory and immune-related diseases .
loading...
    loading...
Cat. No.: HY-184001
CAS No.: 3078683-57-2
LT-1339-553 is a selective, orally active RIPK1 inhibitor with IC50 values of 4.32, 95.74 and 84.33 nM against RIPK1, RIPK2 and RIPK3, respectively. LT-1339-553 exerts anti-necroptotic activity by inhibiting the AKT/PI3K/NF-κB pathway and the IL-17 pathway. LT-1339-553 reduces liver injury, inflammatory responses and collagen deposition. LT-1339-553 can be used in studies related to schistosomiasis-induced liver fibrosis .
loading...
    loading...